Shares of DexCom (NASDAQ: DXCM) have been crashing 39.9% decrease as of 10:20 a.m. ET on Friday. The massive sell-off got here after the continual glucose monitoring (CGM) methods maker introduced its second-quarter outcomes following the market shut on Thursday.
DexCom’s income elevated 15% 12 months over 12 months in Q2 to $1 billion. Nonetheless, that got here in a bit of beneath the typical income estimate of $1.04 billion primarily based on LSEG‘s survey of analysts.
The corporate posted Q2 earnings of $143.5 million, or $0.35 per share, primarily based on usually accepted accounting ideas (GAAP). Its non-GAAP earnings got here in at $174.3 million, or $0.43 per share. This mirrored stable year-over-year development and beat the consensus Wall Avenue adjusted earnings estimate of $0.39 per share.
What buyers disliked essentially the most about DexCom’s Q2 replace
The worst a part of DexCom’s Q2 replace was that the corporate lowered its full-year 2024 steerage. DexCom now expects full-year income of between $4 billion and $4.05 billion. It beforehand forecast income of $4.2 billion to $4.35 billion.
What is going on on? DexCom misplaced market share within the sturdy medical tools (DME) channel. CEO Kevin Sayer additionally mentioned within the Q2 earnings name, “We’re brief a lot of new sufferers as to the place we thought we might be at this cut-off date.” His remark raised considerations that DexCom was feeling the impression of GLP-1 medicine that assist sufferers management their diabetes and shed weight.
Is DexCom inventory a purchase on the sell-off?
With DexCom’s large decline at present, you’d assume the sky was falling for the corporate. That does not seem like the case. Nonetheless, this inventory nonetheless trades at a sky-high ahead earnings a number of. I believe buyers’ finest transfer is to stay on the sidelines till DexCom can show its development will proceed to justify such a steep valuation.
Must you make investments $1,000 in DexCom proper now?
Before you purchase inventory in DexCom, contemplate this:
The Motley Idiot Inventory Advisor analyst group simply recognized what they consider are the 10 finest shares for buyers to purchase now… and DexCom wasn’t one in every of them. The ten shares that made the lower may produce monster returns within the coming years.
Think about when Nvidia made this listing on April 15, 2005… in case you invested $1,000 on the time of our advice, you’d have $688,005!*
Inventory Advisor offers buyers with an easy-to-follow blueprint for achievement, together with steerage on constructing a portfolio, common updates from analysts, and two new inventory picks every month. The Inventory Advisor service has greater than quadrupled the return of S&P 500 since 2002*.
See the ten shares »
*Inventory Advisor returns as of July 22, 2024
Keith Speights has no place in any of the shares talked about. The Motley Idiot recommends DexCom. The Motley Idiot has a disclosure coverage.
Why DexCom Inventory Is Crashing At this time was initially revealed by The Motley Idiot